IJCS | Volume 33, Nº1, January / February 2019

100 Table 1 - Characterization of case reports involving CPA after metoclopramide use Reference Patient Comorbid conditions Metoclopramide Bentsen, Stubhaug (2002) 5 41 years, male SAB; ICH; Pneumonia; 10 mg, iv Tung, Sweitzer, Cutter (2002) 4 38 years, female Scleroderma; SAH; Gangrene; 10 mg, iv Grenier, Drolet (2003) 6 66 years, female PO partial mastectomy; DM2; 10 mg, iv Rumore et al. (2011) 8 62 years, female Preoperative gastrectomy; Obesity; 10 mg, iv Al-shaer, Mustafa, Scalese (2015) 7 28 years, male Abdominal pain; emesis; SAH; DLP; 10 mg, iv SAB: subarachnoid bleeding; ICH: intracranial hypertension; SAH: systemic arterial hypertension; PO: postoperative period; DM2: type 2 diabetes mellitus; DLP: dyslipidemia. 1. van derMeer YG, VenhuizenWA, HeylandDK, Van ZantenARH. Should we stop prescribing metoclopramide as a prokinetic drug in critically ill patients? Crit Care. 2014;18(5):502. 2. MidttunM, Oberg B. Total heart block after intravenous metoclopramide. Lancet. 1994;343(8890):182-3. 3. MalkoffMD, Ponzillo JJ, Myles GL, Gomez CR, Cruz-Flores S. Sinus arrest after administration of intravenous metoclopramide.Ann Pharmacother. 1995;29(4):381-3. 4. Bentsen G, StubhaugA. Cardiac arrest after intravenous metoclopramide – a case of five repeated injections of metoclopramide causing five episodes of cardiac arrest. Acta Anaesthesiol Scand. 2002;46(7):908-910. 5. Stoetzer C, Voelker M, Doll T, Heineke J, Wegner F, LefflerA. Cardiotoxic antiemetics metoclopramide and domperidone block cardiac voltage- gated Na+ channels. Anesth Analg. 2017;124(1):52-60. 6. Tung A, Sweitzer B, Cutter T. Cardiac arrest after labetalol and metoclopramide administration in a patient with scleroderma. Anesth Analg. 2002;95(6):1667-8 References Rodrigues et al. Cardiac arrest after metoclopramide infusion Int J Cardiovasc Sci. 2020;33(1):98-101 Case Report justified need. In our case, the use of metoclopramide persisted even after the gastroparesis was reversed, which may have contributed to the event. However, we emphasize the possibility of the rapid bolus infusion risk, due to its well-known neurotoxicity and, apparently, the cardiotoxic potential evidenced by the sodium channel blockade. Author contributions Conception and design of the research: Rodrigues CAO. Acquisition of data: Rodrigues CAO, Martins RR. Analysis and interpretation of the data: Rodrigues CAO, Cunha EQ, Paula PR, Martins RR. Writing of the manuscript: Rodrigues CAO, Cunha EQ, Martins RR. Critical revision of the manuscript for intellectual content: Rodrigues CAO, Cunha EQ, Paula PR, Martins RR. Monitoring of patient and identification of reaction: Paula PR. Potential Conflict of Interest No potential conflict of interest relevant to this article was reported. Sources of Funding There were no external funding sources for this study. Study Association This study is not associated with any thesis or dissertation work. Ethics approval and consent to participate This study was approved by the Ethics Committee of the Hospital Universitário Onofre Lopes under the protocol number 37091717.0.0000.5292. All the procedures in this study were in accordance with the 1975 Helsinki Declaration, updated in 2013. Informed consent was obtained from all participants included in the study.